Veterinary Medicines

ZIPYRAN XL TABLETS FOR DOGS

Authorised
  • Praziquantel
  • Febantel
  • Pyrantel embonate
Download as PDF

Product identification

Medicine name:
ZIPYRAN XL TABLETS FOR DOGS
ZIPYRAN
Active substance:
  • Praziquantel
  • Febantel
  • Pyrantel embonate
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Praziquantel
    175.00
    milligram(s)
    /
    1.00
    Tablet
  • Febantel
    525.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    504.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:
  • Cardboard box containing 1 blister of 2 tablets
  • Cardboard box containing 2 blisters of 2 tablets
  • Cardboard box containing 5 blisters of 2 tablets
  • Cardboard box containing 12 blisters of 2 tablets
  • Cardboard box containing 16 blisters of 2 tablets
  • Cardboard box containing 24 blisters of 2 tablets
  • Cardboard box containing 30 blisters of 2 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Calier S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Calier S.A.
  • Beaphar B.V.
  • Beaphar B.V.
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • 104301
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0224/002
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Germany
  • Greece
  • Italy
  • Netherlands
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."